News

Algeta partners with Avipep
Enlarge image

ResearchNorway

Algeta partners with Avipep

12.06.2013 - Norway’s cancer radiotherapy specialist Algeta has signed an agreement with Australian antibody developer Avipep Pty Ltd.

Under the terms of the agreement, the Algeta ASA will evaluate a conjugate that couples the Oslo-based company’s alpha-emitter thorium-227 to Avipep’s  Avibody, which targets a number of different solid tumour types. The thorium payload, which triggers DNA double-strand breaks that lead to cell death, have been shown to be highly localised, minimising off-target effects. Algeta has coupled the radionuclide to different cancer-targeting molecules such as Her2 and PDGFRβ

Avipep will provide access to one of its proprietary Avibodies, which the company uses for targeting and labelling tumour cells. Algeta will provide access to chelation and conjugation technologies, as well as to its alpha particle-emitting payload thorium-227. Both companies will contribute financially to the collaboration, which is expected to last for up to one year initially with the option for further cooperation thereafter. No further terms have been disclosed.  Algeta runs already collaborations with Genzyme and Affibody AB to develop Targeted Thorium Conjugates (TTC). After having brought its alpha-emitter radium-223 dichloride to the market, the company now seeks to evaluate targeted approaches of its technology. In contrast to cytotoxic payloads, TTC’s offer the advantage of not being subject to drug resistance.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/algeta-partners-with-avipep.html

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

Events

All Events

Current issue

All issues

Product of the week

Products